Mpex's 'soft drug'

Although bacterial efflux pump inhibitors have been pursued as a potential strategy to reduce antibiotic resistance, none have made it into the clinic because of toxicity. Mpex Pharmaceuticals Inc. thinks its MP-601,205 gets around this problem.

Last week, Mpex submitted an IND to start a Phase Ib dosing trial of ...